Articles by Stephanie Sutton - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Stephanie Sutton

EMA Says Ben Venue's Anticancer Drugs Should be Manufactured in Another Facility

Mar 22, 2012

The European Medicines Agency has recommended that manufacturing processes for two anticancer medicines be transferred from Ben Venue Laboratories to alternative facilities. The decision follows GMP shortcomings identified at the US-based manufacturer in late 2011, and marks the end of the EMA's review of all fourteen centrally authorized medicines that were produced at the site.

GSK Launches UK Apprenticeship Program

Mar 15, 2012

GlaxoSmithKline is launching a new program that will create apprenticeships in several areas including manufacturing and R&D at the company's United Kingdom sites.

EMA Announces Electronic Applications Pilot Program

Mar 15, 2012

The European Medicines Agency has launched a pilot program for submitting centralized marketing authorization applications electronically.

GSK and Daiichi Sankyo Launch Vaccine Venture in Japan

Mar 8, 2012

GlaxoSmithKline and Daiichi Sankyo have formed a joint venture that they claim will create the biggest vaccines company in Japan. The joint venture will seek to improve access to vaccinations in the Asian nation as well as introduce new vaccines.

Lilly Invests EUR 330 Million in Biopharmaceutical Manufacturing

Mar 1, 2012

Eli Lilly plans to invest EUR 330 million ($443.2 million) at its Kinsale location in Ireland to create a new biopharmaceutical commercialization and manufacturing facility.

News: Market Boom for Generics

Mar 1, 2012

The pharma industry has reached the long-dreaded patent cliff, but for copycat products, business is booming.

Pfizer, Zhejiang Hisun Pharmaceuticals Sign Generic-Drug Deal

Feb 23, 2012

Pfizer has signed an agreement with the Chinese biopharmaceutical company Zhejiang Hisun Pharmaceuticals with the objective of establishing a $545-million joint venture to develop and commercialize branded generic medicines in both China and the global market.

South Africa Plans Joint Venture for New API Plant

Feb 16, 2012

The South African government is involved in talks with the Swiss biopharmaceutical company Lonza regarding a joint venture to construct the country's first plant to manufacture APIs for antiretroviral medicines.

EMA Guidance on Genetic Variability

Feb 15, 2012

The EMA has published a guideline that addresses the influence of patients? genetic variability on drug pharmacokinetics.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
FindPharma Custom Search
Click here